The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Astashkin E.I.

GBOU VPO Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Glezer M.G.

GBOU VPO Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

The role of L-carnitine in the energetic metabolism of cardiomyocytes and treatment of cardio-vascular diseases

Authors:

Astashkin E.I., Glezer M.G.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2012;5(6): 58‑65

Read: 9295 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF L-CARNITINE IN THE ENERGETIC METABOLISM OF CARDIOMYOCYTES AND TREATMENT OF CARDIO-VASCULAR DISEASES
THE ROLE OF L-CARNITINE IN THE ENERGETIC METABOLISM OF CARDIOMYOCYTES AND TREATMENT OF CARDIO-VASCULAR DISEASES

To cite this article:

Astashkin EI, Astashkin EI, Glezer MG. The role of L-carnitine in the energetic metabolism of cardiomyocytes and treatment of cardio-vascular diseases. Russian Journal of Cardiology and Cardiovascular Surgery. 2012;5(6):58‑65. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medi­cine. 2024;(12):114-121
Asso­ciation of the subclinical athe­rosclerosis with addi­tional risk factors for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2024;(12):151-155
Personalized approach to treatment choice using a digi­tal profile of patient with cardiovascular diseases: the features of clinical deci­sion-making support service. Russian Cardiology Bulletin. 2024;(4-2):105-112
A pilot study of the rela­tionship between cardiovascular risk and routine mammography data in women. Russian Cardiology Bulletin. 2024;(4-2):154-160
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Risk factors and adve­rse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medi­cine. 2025;(2):31-37
10-year dyna­mics of cardiovascular status in combination with coro­nary angiography data in men of working age in the Arctic region of resi­dence and the south of the Tyumen region. Russian Journal of Preventive Medi­cine. 2025;(4):30-38
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Triglycerides-Glucose Index as an inte­gral biomarker of insu­lin resi­stance and cardiovascular diseases. Russian Journal of Preventive Medi­cine. 2025;(5):124-129
Abstract:

Keywords:

L-carnitine
L-carnitine
mitochondria
mitochondria
cardiac metabolism
cardiac metabolism
cardio-vascular diseases
cardio-vascular diseases

Authors:

Astashkin E.I.

GBOU VPO Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Glezer M.G.

GBOU VPO Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Close metadata

References:

  1. Astashkin E.I., Glezer M.G. Gibel' kletok pri ishemii/reperfuzii serdtsa. Sovremennye podkhody k profilaktike i lecheniyu. M: Medikom 2012; 12.
  2. Glezer M.G., Kiseleva I.V., Novikova M.V., Shokina T.V. Stabil'naya stenokardiya. Posobie dlya vrachei obshchei praktiki. M: Medikom 2010; 120.
  3. Perepech N.B., Nedoshivin O.A., Nesterova I.V. Neoton i tromboliticheskaya terapiya pri infarkte miokarda. Ter arkh 2001; 9: 50-55.
  4. Anand I., Chandrashekhan Y., De Giuli F. et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998; 12: 3: 291-299.
  5. Arsenian M.A. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 1997; 40: 3: 265-286.
  6. Bartels G.L., Remme W.J., Holwerda K.J., Kruijssen D.A. Anti-ischaemic efficacy of L-propionylcarnitine - a promising novel metabolic approach to ischaemia? Eur Heart J 1996; 17: 3: 414-420.
  7. Bartels G.L., Remme W.J., Pillay M. et al. Acute improvement of cardiac pump function with intravenous L-propionylcarnitine in humans. J Cardiovasc Pharmacol 1992; 20: 1: 157-164.
  8. Bartels G.L., Remme W.J., Pillay M. et al. Effects of L-propionylcamitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 1994; 74: 2: 125-130.
  9. Brass E.P. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002; 54: 4: 589-598.
  10. Cacciatore L., Cerio R., Ciarimboli M. et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res 1991; 17: 4: 225-235.
  11. Canale C., Terrachini V., Biagini A. et al. Bicycle ergometer and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: Semiautomatic computerized analysis of M-mode tracings. Int J Clin Pharmacol Ther Toxicol 1988; 26: 4: 221-224.
  12. Cave M.C., Hurt R.T., Frazier T.H. et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract 2008; 23: 1: 16-34.
  13. Cevese A., Schena F., Cerutti G. Short-term hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs. Cardiovasc Drugs Ther 1991; 5: 45-56.
  14. Chang B., Nishikawa M., Sato E. et al. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 2002; 405: 1: 55-64.
  15. Cherchi A. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985; 23: 10: 569-572.
  16. Cherchi A., Lai C., Onnis E. et al. Propionylcarnitine in stable effort angina. Cardiovasc Drugs Ther 1990; 4: 2: 481-486.
  17. Chiariello M., Nrevetti G., Policicclio A. et al. L-Carnitine in acute myocardial infarction. A multicentre randomized trial. In: Clinical aspects of human carnitine deficiency. Ed. A. Borum. New York: Pergamon Press 1986; 242-243.
  18. Cisowski M., Bochenek A., Kucewicz E. et al. The use of exogenous creatine phosphate for myocardial protection in patients undergoing coronary artery bypass surgery. J Cardiovasc Surg 1996; 37: 6: Suppl 1: 75-80.
  19. Corbucci G.G., Menichetti A., Cogliatti A. et al. Metabolic aspects of acute tissue hypoxia during extracorporeal circulation and their modification induced by L-carnitine treatment. Int J Clin Pharmacol Res 1992; 12: 3: 149-157.
  20. Corbucci G.G., Loche F. L-carnitine in cardiogenic shock therapy: pharmacodynamic aspects and clinical data. Int J ClinPharmacol Res 1993; 13: 2: 87-91.
  21. Davini P., Bigalli A., Lamanna F., Boem A. Controlled study on L-carnitine therapeutic efficacy in post infarction. Drug Exp Clin Res 1992; 18: 8: 355-365.
  22. De Giuli F., Pasini E., Opasich C. et al. Effects of propionyl-L-carnitinein patients with heart failure. J Mol Cell Cardiol 1995; 27: 44.
  23. Duncker D.J., Sassen L.M.A., Bartels G.L. et al. L-propionylcarnitine does not affect myocardial metabolic or functional response to chronotropic and inotropic stimulation following repetitive ischemia in anesthetized pigs. J Cardiovasc Pharmacol 1993; 22: 3: 488-498.
  24. Ferrari R., Merli E., Cicchitelli G. et al. Therapeutic effecs of L-carnitine and propionyl-L-carnitine on cardiovascular disease: a review. Ann N Y Acad Sci 2004; 1033: 79-91.
  25. Flanagan J.L., Simmons P.A., Vehige J. et al. Role of carnitine in disease. Nutr Metab 2010; 7: 30-43.
  26. Folts J., Shug Al., Koke Jr., Bittar N. Protection of the ischemic dog myocardium with carnitine. Am J Cardiol 1978; 41: 7: 1209-1214.
  27. Furuno T., Kanno T., Arita K. et al. Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol 2001; 62: 8: 1037-1046.
  28. Ghidini O., Azzurro M., Vita G., Sartori G. Evaluation of the therapeutic effcacy of L-carnitine in congestive heart failure. Int J Clin Pharmacol Ther Toxicol 1988; 26: 4: 217-220.
  29. Iliceto S., Scrutinio D., Bruzzi P. et al. Effect of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol 1995; 26: 2: 380-387.
  30. Indiveri C., Iacobazzi V., Tonazzi A. et al. The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology. Mol Aspects Med 2011; 32: 4-6: 223-233.
  31. Iyer R.N., Khan A.A., Gupta A. et al. L-carnitine moderately improves the exercise tolerance in chronic stable angina. J Ass Phys India 2000; 48: 1: 1050-1052.
  32. Kamikawa T., Suzuki Y., Kobayashi A. et al. Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris. Jpn Heart J 1984; 25: 4: 587-597.
  33. Lagioia R., Scrutinio D., Mangini S.G. et al. Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol 1992; 34: 2: 167-172.
  34. Lango R., Smolen'ski R.T., Rogowski J. et al. Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc Drugs Ther 2005; 19: 4: 267-275.
  35. Lee K., Kerner J., Hoppel Ch.L. Mitochondrial carnitinepalmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex. J Biol Chem 2011; 286: 29: 25655-25662.
  36. Liedtke Aj., Nellis S.H. Effects of carnitine in ischemic and fatty acid supplemented swine heart. J Clin Invest 1979; 64: 2: 440-447.
  37. Lopaschuk G.D., Ussher J.R., Folmes C.D.L. et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010; 90: 1: 207-258.
  38. Mancini M., Rengo F., Lingetti M. et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitinein patients with congestive heart failure. Arzneimittelforschung 1992; 42: 9: 1101-1104.
  39. Martina B., Zuber M., Weiss P. et al. Anti-arrhythmia treatment using L-carnitine in acute myocardial infarct. Schweiz Med Wochenschr 1992; 122: 37: 1352-1355.
  40. Mondillo S., Faglia S., D'Aprile N. et al. Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine Clin Ter 1995; 146: 12: 769-774.
  41. Noland R.C., Koves T.R., Seiler S.E. et al. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem 2009; 284: 34: 22840-22852.
  42. Oyanagi E., Yano H., Kato Y. et al. L-Carnitine suppresses oleic acid-induced membrane permeability transition of mitochondria. Cell Biochem Funct 2008; 26: 7: 778-786.
  43. Palazzuoli V., Mondillo S., Faglia S. et al. The evaluation of antiarrhythmic activity of L-carnitine and propafenone in ischemic cardiomyopathy. Clin Ter 1993; 142: 2: 155-159.
  44. Pillich R.T., Scarsella G., Risuleo G. Reduction of apoptosis through the mitochondrial pathway by the administration of acetyl-L-carnitine to mouse fibroblasts in culture. Exp Cell Res 2005; 306: 1: 1-8.
  45. Pucciarelli G., Mastursi M., Latte S. et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure. Clin Ter 1992; 141: 11: 379-384.
  46. Rebouche Ch.J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitinemetabolism. Ann N Y Acad Sci 2004; 1033: 1: 30-41.
  47. Rebuzzi A.G., Schiavoni G., Amico C.M. et al. Beneficial effect of L-carnitine in the reduction of necrotic area in acute myocardial infarction. Drugs Exp Clin Res 1984; 10: 219-223.
  48. Regitz V., Bossaller C., Strasser R. et al. Metabolic alterations in end-stage and less severe heart failure - myocardial carnitine decrease. J Clin Chem Clin Biochem 1990; 28: 9: 611-617.
  49. Regitz V., Shug A.L., Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 1990; 65: 11: 755-760.
  50. Regitz V., Fleck E. Role of carnitine in heart failure. In: L-carnitine and Its Role in Medicine: From Function to Therapy. Eds. R. Ferrari, S. Di Mauro, G. Sherwood. New York: Academic Press 1992; 295-323.
  51. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000; 139: 2 Pt: 3: S120-S123.
  52. Rizzon P., Biasco G., Di Biase M. et al. High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. Eur Heart J 1989; 10: 6: 502-508.
  53. Ruda M.Ya., Samarenko M.B., Afonskaya N.I., Saks V.A. Reduction of ventricular arrhythmias by phosphocreatine (Neoton) in patients with acutemyocardial infarction. Am Heart J 1988; 116: 2: Pt 1: 393-397.
  54. Sassen L.M.A., Bezstarosti K., Van der Giessen W.J. et al. L-propionylcarnitine increases postischemic blood flow but does not affect recovery of the energy charge. Am J Physiol 1991; 261: 1: Pt 2: H172-H180.
  55. Serati A.R., Motamedi M.R., Emami S. et al. L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology 2010; 116: 3: 178-182.
  56. Sharma Sh., Black St.M. Carnitine homeostasis, mitochondrial function, and cardiovascular disease. Drug Disc Today Dis Mech 2009; 6: 1-4: e31-e39.
  57. Sharma Sh., Sud N., Wiseman D.A. et al. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 294: 1: L46-L56.
  58. Shrago E., Shug Al., Sul H. et al. Control of energy production m myocardial ischemia. Circ Res 1976; 38: Suppl 1: 75-79.
  59. Shug Al., Thomsen Jh., Folts Jd. et al. Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia. Arch Biochem Biophys 1978; 187: 1: 25-33.
  60. Singh R.B., Niaz M.A., Agarwal P. et al. A randomized, double-blind, placebo controlled trial of L-carnitine in suspected myocardial infarction. Postgrad Med J 1996; 72: 843: 45-50.
  61. Spagnoli L.G., Corsi M., Villaschi S. et al. Myocardial carnitine deficiency in acute myocardial infarction. Lancet 1982; 1: 8286: 1419-1420.
  62. Sparagna G.C., Hickson-Bick D.L., Buja L.M., McMillin J.B. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 2000; 279: 5: 2124-2132.
  63. Stanley C.A. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004; 1033: 42-51.
  64. Steifa M., Zeman K., Groch L. et al. The effect of creatine phosphate (Neoton) in acute myocardial infarct (a prospective multicenter pilot study). Vnitr Lek 1993; 39: 2: 136-142.
  65. Suzuki Y., Masumura Y., Kobayashi A. et al. Myocardial carnitinedeciency in chronic heart failure. Lancet 1982; 1: 8263: 116.
  66. Tamai I., Ohashi R., Nezu J. et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. 1998; 273: 32: 20378-20382.
  67. Tarantini G., Scrutinio D., Bruzzi P. et al. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 2006; 106: 4: 215-223.
  68. THE EMIP-FR GROUP Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy A double-blind, placebo-controlled, randomized trial. Eur Heart J 2000; 21: 18: 1537-1546.
  69. van der Horst I.C., Zijlstra F., van't Hof A.W.J. et al. Infarct Study Group: Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. The glucose-insulin-potassium study: a randomized trial. J Am CollCardiol 2003; 42: 5: 784-791.
  70. vanVlies N., Ferdinandusse S., Turkenburg M. et al. PPAR-alpha activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitin accumulation. Biochem Biophys Acta 2007; 1767: 9: 1134-1142.
  71. Vaz F.M., Wanders R.J. Carnitine biosynthesis in mammals. Biochem J 2002; 361: Pt 3: 417-429.
  72. Wall B.T., Stephens F.B., Constantin-Teodosiu D. et al. Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. J Physiol 2011; 589: 4: 963-973.
  73. Weber P., Vlasicová Y., Lábrová R., Semrád B. Use of creatine phosphate in treatment of cardio-cerebral syndrome associated with acute myocardial infarct in the aged. Cas Lek Cesk 1995; 134: 2: 53-56.
  74. Wittels B., Spann J.F. Defective lipid metabolism in the failing heart. J Clin Invest 1968; 47: 1787-1794.
  75. Xue Y.Z., Wang L.X., Liu H.Z. et al. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther 2007; 21: 6: 445-448.
  76. Ye J., Li J., Yu Y. et al. L-carnitine attenuates oxidant injury in HK-2 cells via ROS-mitochondria pathway. Regul Pept 2010; 161: 1-3: 58-66.
  77. Zhu X., Sato E.F., Wang Y. et al. Acetyl-L-carnitine suppresses apoptosis of thioredoxin 2-deficient DT40 cells. Arch Biochem Biophys 2008; 478: 2: 154-160.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.